<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868634</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-080-2</org_study_id>
    <secondary_id>2008-003779-37</secondary_id>
    <nct_id>NCT00868634</nct_id>
  </id_info>
  <brief_title>Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer</brief_title>
  <acronym>CARIN</acronym>
  <official_title>Capecitabine and Bevacizumab ± Vinorelbine as 1st Line Treatment in HER-2 Negative Metastatic or Locally Advanced Inoperable Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitskreis Klinische Studien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to detect the superiority of the triple combination of capecitabine,
      bevacizumab and vinorelbine versus the combination of capecitabine and bevacizumab in
      patients with metastatic breast cancer. 600 patients, 300 in each treatment group, are
      treated until progression of disease to determine PFS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>end of trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events and serious adverse events</measure>
    <time_frame>during the whole time of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR = CR +PR)</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine / Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine / Bevacizumab / Vinorelbine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Xeloda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>15 mg/kg i.v., day 1 Cycles are repeated every three weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Avastin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Xeloda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>15 mg/kg i.v., day 1. Cycles are repeated every three weeks.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Avastin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
    <description>25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Navirel®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Written informed consent.

          -  Able to comply with the protocol.

          -  ECOG Performance status 0 - 2.

          -  Life expectancy more than 12 weeks.

          -  Known ER / PR status.

          -  Confirmed HER2/neu-negative, adenocarcinoma of the breast with measurable or
             non-measurable locally recurrent or metastatic disease, who are candidates for
             chemotherapy.

          -  Previous (neo)adjuvant chemotherapy is allowed provided that the last dose of
             chemotherapy was applied more than 6 months prior to randomization.

          -  Previous adjuvant radiotherapy is allowed as part of the treatment of early breast
             cancer provided that no more than 30% of marrow-bearing bone was irradiated.

          -  No signs and symptoms of CHF.

          -  Adequate hepatic and renal function values.

          -  Adequate hematologic function values.

        Key Exclusion Criteria:

          -  Pregnant or lactating females.

          -  Previous chemotherapy for metastatic or locally recurrent breast cancer.

          -  Previous radiotherapy for the treatment of metastatic disease (unless given for the
             relief of metastatic bone pain)

          -  Evidence of spinal cord compression or current evidence of central nervous system
             (CNS) metastases.

          -  Major surgical procedure, open biopsy or significant traumatic in-jury within 28 days
             prior to randomization, or anticipation of the need for major surgery during the
             course of the study treatment.

          -  History or evidence of inherited bleeding diathesis or coagulopathy with the risk of
             bleeding.

          -  Uncontrolled hypertension (systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg).
             Clinically significant (i.e. active) cardiovascular disease, requiring medication
             during the study and might interfere with regularity of the study treatment, or not
             controlled by medication.

          -  Non-healing wound, active peptic ulcer or bone fracture.

          -  History of abdominal fistula, or any grade 4 nongastrointestinal fistula,
             gastrointestinal perforation or intrabdominal abscess within 6 months of
             randomization.

          -  Active infection requiring i.v. antibiotics at randomization.

          -  Clinically significant malabsorption syndrome or inability to take oral medication.

          -  Known hypersensitivity to any of the study drugs or excipients.

          -  Concurrent treatment with any drug interfering with study medication. Concurrent
             participation in another clinical trial. Prior participation is allowed when the last
             study medication was applied more than 4 weeks prior to randomization.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna Hegewisch-Becker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onkologische Schwerpunktpraxis Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

